scholarly journals Retinol binding protein 1 affects Xenopus anterior neural development via all‐trans retinoic acid signaling

2021 ◽  
Author(s):  
Hannah Flach ◽  
Thomas Basten ◽  
Corinna Schreiner ◽  
Petra Dietmann ◽  
Sara Greco ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Neural Development ◽  
Binding Protein ◽  
Retinol Binding Protein ◽  
Retinoic Acid Signaling ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

scholarly journals All-Trans Retinoic Acid Induces Cellular Retinol-Binding Protein in Human Skin In Vivo

1995 ◽  
Vol 105 (1) ◽  
pp. 80-86 ◽  
Author(s):  
Gary J. Fisher ◽  
Ambati P. Reddy ◽  
Subhash C. Datta ◽  
Sewon Kang ◽  
Jong Y. Yi ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Human Skin ◽  
Binding Protein ◽  
Retinol Binding Protein ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid ◽  
Cellular Retinol Binding Protein

scholarly journals Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells [see comments]

Blood ◽  
1993 ◽  
Vol 82 (7) ◽  
pp. 2175-2181 ◽  
Author(s):  
L Delva ◽  
M Cornic ◽  
N Balitrand ◽  
F Guidez ◽  
JM Miclea ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Acute Promyelocytic Leukemia ◽  
Induction Therapy ◽  
Binding Protein ◽  
Promyelocytic Leukemia ◽  
Leukemic Cells ◽  
Differentiation Induction ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

Abstract All-trans retinoic acid (ATRA) induces leukemic cell differentiation and complete remission (CR) in a high proportion of patients with acute promyelocytic leukemia (AML3 subtype). However, relapses occur when ATRA is prescribed as maintenance therapy, and resistance to a second ATRA-induction therapy is frequently observed. An induced hypercatabolism of ATRA has been suggested as a possible mechanism leading to reduced ATRA sensitivity and resistance. CRABPII, an RA cytoplasmic binding protein linked to RA's metabolization pathway, is induced by ATRA in different cell systems. To investigate whether specific features of the AML3 cells at relapse could explain the in vivo resistance observed, we studied the CRABP levels and in vitro sensitivity to ATRA of AML3 cells before and at relapse from ATRA. Relapse-AML3 cells (n = 12) showed reduced differentiation induction when compared with “virgin”-AML3 cells (n = 31; P < .05). Dose-response studies were performed in 2 cases at relapse and showed decreased sensitivity to low ATRA concentrations. CRABPII levels and in vitro differentiation characteristics of AML3 cells before and at relapse from ATRA therapy were studied concomittantly in 4 patients. High levels of CRABPII (median, 20 fmol/mg of protein) were detected in the cells of the 4 patients at relapse but were not detected before ATRA therapy. Three of these patients showed a decrease in differentiation induction of their leukemic cells, and a failure to achieve CR with a second induction therapy of ATRA 45 mg/m2/day was noted in all patients treated (n = 3). Results from this study provide evidence to support the hypothesis of induced-ATRA metabolism as one of the major mechanisms responsible for ATRA resistance. Monitoring CRABPII levels after ATRA withdrawal may help to determine when to administer ATRA in the maintenance or relapse therapy of AML3 patients.

scholarly journals Docosahexaenoic Acid Reverted the All-trans Retinoic Acid-Induced Cellular Proliferation of T24 Bladder Cancer Cell Line

2020 ◽  
Vol 9 (8) ◽  
pp. 2494
Author(s):  
Lara Costantini ◽  
Romina Molinari ◽  
Barbara Farinon ◽  
Veronica Lelli ◽  
Anna Maria Timperio ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Retinoic Acid ◽  
Docosahexaenoic Acid ◽  
Cell Line ◽  
Cellular Proliferation ◽  
Binding Protein ◽  
Cellular Growth ◽  
Bladder Cancer Cell Line ◽  
Trans Retinoic Acid ◽  
All Trans Retinoic Acid

The treatment of solid cancers with pharmacological all-trans retinoic acid (ATRA) concentrations, even if it is a gold standard therapy for the acute promyelocytic leukaemia (APL), is not always effective due to some resistance mechanisms. Here the resistance to ATRA treatment of T24 cell line, bladder cancer, was investigated. T24 was not only resistant to cell death when treated at concentrations up to 20 µM of ATRA, but it was also able to stimulate the cellular proliferation. An over-expression of the fatty acid binding protein 5 (FABP5) in conjunction with the cellular retinol-binding protein-II (CRABP-II) down-expression was found. However, the direct inhibition of the peroxisome proliferator-activated receptor β/δ (PPARβ/δ) did not abolish T24 proliferation, but rather potentiated it. Moreover, considering the ability of the long-chain fatty acids (LCFAs) to displace ATRA from FABP5, the actions of the saturated palmitic acid (PA), unsaturated omega-6 linoleic acid (LA) and omega-3 docosahexaenoic acid (DHA) were evaluated to counteract ATRA-related proliferation. ATRA-PA co-treatment induces cellular growth inhibition, while ATRA-LA co-treatment induces cellular growth enhancement. However, even if DHA is unsaturated LCFA as LA, it was able to reverse the ATRA-induced cellular proliferation of T24, bringing the viability percentages at the levels of the control.

Sign in / Sign up

Export Citation Format

Share Document